In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Hyseq acquires Variagenics in reverse merger

Executive Summary

In a reverse merger, gene sequencing company Hyseq will acquire pharmacogenomics firm Variagenics in a tax-free stock-for-stock transaction valued at approximately $56.4mm, which includes options and warrants. Each outstanding Variagenics common share will be exchanged for 1.645 shares of Hyseq common stock, worth about $2.24 based on the 10-day market average.
Deal Industry
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Stock
    • Reverse Acquisition

Related Companies